9-benzyl-3-methylene-1,5-ditosyl-1,5,9-triazacyclododecane

ID: ALA1852155

Chembl Id: CHEMBL1852155

Cas Number: 182316-44-5

PubChem CID: 466371

Max Phase: Preclinical

Molecular Formula: C31H39N3O4S2

Molecular Weight: 581.80

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Synonyms from Alternative Forms(1): Cyclotriazadisulfonamide HCl

Canonical SMILES:  C=C1CN(S(=O)(=O)c2ccc(C)cc2)CCCN(Cc2ccccc2)CCCN(S(=O)(=O)c2ccc(C)cc2)C1

Standard InChI:  InChI=1S/C31H39N3O4S2/c1-26-11-15-30(16-12-26)39(35,36)33-21-7-19-32(25-29-9-5-4-6-10-29)20-8-22-34(24-28(3)23-33)40(37,38)31-17-13-27(2)14-18-31/h4-6,9-18H,3,7-8,19-25H2,1-2H3

Standard InChI Key:  SRJIECKMPIRMJJ-UHFFFAOYSA-N

Associated Targets(Human)

SORT1 Tchem Neurotensin receptor 3 (102 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CD4 Tclin T-cell surface antigen CD4 (114 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 581.80Molecular Weight (Monoisotopic): 581.2382AlogP: 4.84#Rotatable Bonds: 6
Polar Surface Area: 78.00Molecular Species: NEUTRALHBA: 5HBD:
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): #RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 7.36CX LogP: 4.98CX LogD: 4.70
Aromatic Rings: 3Heavy Atoms: 40QED Weighted: 0.39Np Likeness Score: -0.92

References

1. Chawla R, Van Puyenbroeck V, Pflug NC, Sama A, Ali R, Schols D, Vermeire K, Bell TW..  (2016)  Tuning Side Arm Electronics in Unsymmetrical Cyclotriazadisulfonamide (CADA) Endoplasmic Reticulum (ER) Translocation Inhibitors to Improve their Human Cluster of Differentiation 4 (CD4) Receptor Down-Modulating Potencies.,  59  (6): [PMID:26974263] [10.1021/acs.jmedchem.5b01832]
2. Lumangtad LA, Bell TW..  (2020)  The signal peptide as a new target for drug design.,  30  (10): [PMID:32209293] [10.1016/j.bmcl.2020.127115]

Source